ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Sarepta’s very bad week"
Episode Synopsis
Things don’t look good for Sarepta. After reports of a third patient death on Thursday — this one in a clinical trial — which wasn’t disclosed by the company in its corporate update, an HHS official told Endpoints that the FDA would ask the company to stop shipping its Duchenne muscular dystrophy treatment Elevidys. Stock is down. Leadership is under fire for not being transparent about patient deaths. Where does the company, and the gene therapy industry, go from here?
More episodes of the podcast Post-Hoc Live
The plan to make more custom CRISPR therapies — w Kiran Musunuru & Rebecca Ahrens-Nicklas
03/11/2025
The fight over Metsera
03/11/2025
Breaking down the XBI — with Josh Schimmer
10/09/2025
Choosing the Endpoints 11
03/09/2025
In God we trust